n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, September 28th, 2015

The QualityStocks
Daily Stock List

graphic
graphic

Cannabics Pharmaceuticals, Inc. (CNBX)

SmallCapVoice reported recently on Cannabics Pharmaceuticals, Inc. (CNBX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Cannabics Pharmaceuticals, Inc.’s dedication is to the development of advanced cannabinoid-based treatments and therapies. Its principal emphasis is the development of novel therapies and biotechnological tools targeted to providing palliative and anticancer treatments. Cannabics Pharmaceuticals lists on the OTC Markets’ OTCQB. Founded in 2012, the Company has its headquarters in Bethesda, Maryland.

The advanced tools include novel delivery systems and the discovery of cannabinoid compounds targeted to specific cancers based on pioneering High Through-output Screening and bioinformatics. Cannabics’ main technology is Cannabics SR. This is a patented technology for a long-acting oil capsule, which provides a safe, effective and reliable administration of cannabis. This technology is composed exclusively from food grade materials. The technology at 25mg delivers a steady level of beneficial effects for 10–12 hours.

Since 2012, Cannabics Pharmaceuticals has been developing an integrated treatment for cancer patients via a network of doctors, hospitals, universities and agronomists in Israel. By way of its Research and Development (R&D) extension in Israel, it is developing a broad spectrum pipeline of advanced cannabinoid based therapies. Through collaboration with major medical centers in Israel, Cannabics’ is investigating the beneficial effects of its products in varied indications.

Recently, Cannabics Pharmaceuticals announced that WanaCapsXR capsules sell in every region of Colorado. WanaCapsXR is the result of a partnership between Wana Brands from Boulder, Colorado and Cannabics Pharmaceuticals. The two companies decided to expand into more key medical marijuana markets. These markets include Oregon, New York, Washington, Nevada and California.

Earlier this month, Cannabics Pharmaceuticals announced that Israeli patients with a medical cannabis license will now have access to Cannabics Pharmaceutical's cannabis oil Capsules. The Company executed an Intellectual Property (IP) Licensing and Collaboration Agreement in Israel with Bazelet Pharma. The Agreement is for the distribution of Cannabics Pharmaceuticals’ medical cannabis capsules in Israel via approved medical cannabis growers and in strict compliance with all laws and regulations in Israel.

Cannabics Pharmaceuticals, Inc. (CNBX), closed Monday's trading session at $0.06, down 20.00%, on 65,430 volume with 15 trades. The average volume for the last 60 days is 18,945 and the stock's 52-week low/high is $0.06/$0.49.

Silver Bull Resources, Inc. (SVBL)

Wall Street Resources, RedChip, Streetwise Reports, and Stockhouse reported on Silver Bull Resources, Inc. (SVBL), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Silver Bull Resources, Inc. is a mineral exploration company headquartered in Vancouver, British Columbia. The Company’s flagship project is "Sierra Mojada". This Project is situated 150 kilometers north of the city of Torreon in Coahuila, Mexico. The Project is highly prospective for silver and zinc. An exploration stage enterprise, the Company previously went by the name Metalline Mining Company. It changed its corporate name to Silver Bull Resources, Inc. in April of 2011.

The Sierra Mojada Project is 100 percent owned and operated by Silver Bull Resources. It is part of a large land package comprising 40 mining concessions totaling 21,167 hectares (52,305 acres), positioned in a historical high grade silver, lead, zinc mining district discovered in 1879.

The Sierra Mojada Project has an NI 43-101 compliant measured and indicated Global resource of 58.7 million tonnes grading at 3.6% zinc and 50 g/t silver for 4.670 billion pounds of zinc and 90.8 million ounce of silver.

The primary zone of mineralization found at Sierra Mojada extends over 6 kilometers in an East-West direction along the base of the Sierra Mojada Range parallel with the Sierra Mojada fault. More than 54 historical mine shafts lie along this strike, mining to depths greater than 200 meters. This area has not been mined with modern mining technology and processes.

This past June, Silver Bull Resources announced that it identified more high grade massive sulphide mineralization at its Sierra Mojada Project in Coahuila, Northern Mexico. The Company identified new massive sulphide mineralization grading 690G/T Silver, 1% Copper, 4.8% Lead and 15.25% Zinc at the Sierra Mojada Project.

The new sulphide mineralization lies within a 1.4 kilometer long east-west trending chargeability anomaly identified in a "Gradient Array IP survey" completed in 2010 by Zonge Engineering and Research Organization, Inc. Sierra Mojada is an open pittable oxide deposit.

Silver Bull Resources, Inc. (SVBL), closed Monday's trading session at $0.0553, down 10.08%, on 78,300 volume with 23 trades. The average volume for the last 60 days is 99,334 and the stock's 52-week low/high is $0.05/$0.2395.

Cell MedX Corp. (CMXC)

The Observer, StockBlogs and SECFilings.com News reported recently on Cell MedX Corp. (CMXC), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Cell MedX Corp. is an early development stage company headquartered in Henderson, Nevada. It centers on the discovery, development, and commercialization of therapeutic products for patients with diseases, including diabetes, through developing technologies to help manage the illness and related complications. Cell MedX manufactures and distributes medical devices that are powered by its proprietary, patented technology of low level current chiefly for supporting chemical (pharmaceutical) treatments for diabetes. Cell MedX lists on the OTC Bulletin Board.

Cell MedX is at the vanguard of creating devices that treat chronic and acute conditions for clinical and self-management care. It is making safe, results-oriented technologies combining electro-chemical applications and establishing new levels of treatment, called cellular medicine. Additionally, through its wholly-owned subsidiary, Avyonce Cosmedics, Inc., Cell MedX engages in the reselling and marketing of technology and equipment to the worldwide wellness industry and also providing continuing education to health care professionals.

Cell MedX’s objective is to release its first lineup of commercial products in early 2016. The Company will begin with its flagship product named ‘e-Balance’, which works to improve the efficacy of the client’s existing medication regimes. The e-Balance brand includes consumer product development and professional versions for use within medical facilities. The design of them are to address accelerated wound healing, abatement of diabetic neuropathies, improvement with glucose control, insulin resistance and blood pressure.

Cell MedX announced this past April further results of the continuing analysis of metabolomic assays taken during the Phase 1 pilot clinical trial. The pilot clinical discovery phase trial in two diabetic subjects took place in January 2015. Ongoing metabolomic analyses of the samples yielded more insights into the immediate metabolic alterations brought about by a single e-Balance technology treatment. In addition to indications of increased sensitivity to insulin, glycolytic processes are also clearly upregulated. These new findings reveal enhanced transport and use of glucose during a treatment.

This past July, Cell MedX updated the timeline of its clinical trials concerning its innovative and proprietary technology branded under the trade name e-Balance. The program aims to accurately measure and quantify e-Balance's ability to alter key metabolic pathways targeting improved blood sugar control in patients living with diabetes. Regarding the Phase II-A Clinical Trial, recruitment for the controlled clinical trial in Orange County, California is underway and targeting 30 type 1 and type 2 diabetes patients over 6 weeks. The clinical trial is to progress over 6-8 months, with clinical end points including reduction in HbA1C independent of other factors.

Moreover, investigations continue into precise metabolic changes and pathways consistent with overall improved glycemic control. The Company is looking to precisely define optimal parameters and settings based on individual discoverable factors. Selective testing will take place to further clarify the cell and organ level mechanism of the core technology.

Cell MedX Corp. (CMXC), closed Monday's trading session at $0.15, up 6.99%, on 16,300 volume with 5 trades. The average volume for the last 60 days is 30,656 and the stock's 52-week low/high is $0.014/$0.81.

Airware Labs Corp. (AIRW)

Stock Commander, MyBestStockAlerts, PremiereStockAlerts, and Real Pennies reported on Airware Labs Corp. (AIRW), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Airware Labs Corp. is an innovator in ground-breaking breathing devices and skin care products that enhance quality of life, personal health, and well-being. Airware Labs studies the effects of environmental factors on breathing and the human body. It also studies the scientifically shown benefits provided by the strategic use of therapeutic essential oils. Airware Labs is based in Scottsdale, Arizona.

The Company’s products address important personal health and quality of life issues providing antibacterial and therapeutic defense against airborne bacteria, viruses, and allergens, and also congestion, snoring, insomnia, nausea, headaches, and an athletic performance enhancing breathing aid that increases oxygen to fuel cells in the body.

Airware Labs’ products are marketed under the brand name of AIR®. Its product family includes air BREATHE, air ALLEREGY, air TRAVEL, air Essentials SLEEP/SNORE, air Essentials NAUSEA, air Essentials HEADACHE, air Essentials DECONGEST, and air SPORT.

The Company sells its products through partners, including Wal-Mart, CVS, Walgreens, Albertsons, Drugstore.com, Acme, Shoppers, Shop n' Save, Farm Fresh, and individuals in the U.S., Canada, and Europe.

Airware Labs has introduced a new line of skin care products. These products use pharmaceutical-grade serums in a patented treatment system designed to enhance and provide youthful benefits to the skin. The first product in its skin care line uses a high-grade vitamin C serum combined with a patented protective shield to target facial wrinkles. Following this anti-wrinkle product, Airware will launch skin care systems to treat acne, scars, and warts.

The Company has filed numerous new patent applications for a unique nasal drug delivery system. This system will enable users to inhale precise doses of medication into the nasal cavity. The system will include Airware’s patent-pending disposable sealed cartridge and patent-pending nasal insert system with insufflation plugins. Both of these can be filled with medication in powder form.

In August, Airware Labs announced that Korea's SHINSEGAE department stores will sell Airware Labs' AIR™ Defense product. SHINSEGAE presently operates 10 regional department stores, 2 premium food market stores, and the popular online shopping site, SHINSEGAE Mail. SHINSEGAE Centurn City is the world's largest department store.

Moreover, in August, Airware Labs announced the appointment of Dr. Dan Cohen to the newly created position of President of Airware Labs. Dr. Cohen is the former Founder, Chairman and CEO of CNS, Inc. He was the mover behind the swift rise of Breathe Right nasal strips, acquiring the rights to manufacture and sell the product for the medical equipment company he created in 1982.

Airware Labs Corp. (AIRW), closed Monday's trading session at $0.15, even for the day, on 2,000 volume with 1 trade. The average volume for the last 60 days is 25,871 and the stock's 52-week low/high is $0.0407/$0.299.

Urban Barns Foods, Inc. (URBF)

Greenbackers, SmallCapVoice, Epic Stock Picks, EpicVIP Group, Jet-Life Penny Stocks, CrazyStocks, Chatter Box Stocks, SpecialPennyStocks, MadMoneyPennyStocks, AwesomeStocks, TerrificPennyStocks, and SquawkBoxStocks reported previously on Urban Barns Foods, Inc. (URBF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed Urban Barns Foods, Inc. employs patent pending and proprietary equipment to produce affordable vegetables in a secure and controlled indoor environment. The Company sets up subsidiary facilities and grows locally. As a result, Urban Barns can focus on supplying any community, regardless of the regional climate. This effectively reduces shipping times and related spoilage costs. The Company can scale and cater to the demands of all major communities.

Urban Barns Foods has developed patent pending Cubic Farming™ technology. This is a type of Controlled Environment Agriculture (CEA). The Company’s rigorous food safety and quality control policies and procedures follow the Global Food Safety Initiative (GFSI) guidelines. Its products include Microgreens, Butterhead Lettuce, Red Oak Leaf Lettuce, Red Romaine, Basil, and Red Leaf Lettuce. In essence, Urban Barns Foods is a vertical farming enterprise, which produces Kosher-certified leafy vegetables using its proprietary Cubic Farming™ technology. Its produce is picked at the peak of ripeness.

The Company’s commitment is to growing consistent, healthy, and fresh vegetables year round. The vegetables are grown in a completely controlled environment. Moreover, its vegetables are grown from non-GMO (genetically modified organism) seeds and free of pesticide, herbicide, and fungicide. There is no contact with the outside world. Therefore, this eliminates the possibilities of contamination and infection.

The Company has completed the Phase 1 development of its new facility in Mirabel, Quebec. The facility covers 10 growing machines plus three research and development (R&D) machines to be used by McGill University on site.

Urban Barns Foods is now growing varieties of lettuce, micro greens, and fine herbs. It is supplying many local restaurants with produce picked and delivered on the same day. Planning is taking place for Phase 2 development with a new much larger Cubic Farming growing machine prototype.

The Company has its R&D activities at McGill University. The Biomass Production Laboratory at McGill University, with support from Urban Barns Foods, is leading the way for research in urban agriculture.

The Urban Barns facility in Mirabel, Quebec (benefiting from the Biomass Production Laboratory expertise) opened in June 2014. It has begun selling pesticide and GMO-free lettuce to clients in the provinces of Quebec and Ontario. A Cubic Farming™ research unit has been assembled on the McGill MacDonald campus to assist in measuring photosynthetic efficiency of horticultural plants and further developing LED technology.

In May of this year, Urban Barns Food announced that it received the MK Kosher certification for its Oak Leaf lettuce and three types of Micro Greens: Daikon, Sango/Rambo and Mizuna. The Company will continue to expand its Kosher product family with more micro green varieties and herbs.

Urban Barns Foods, Inc. (URBF), closed Monday's trading session at $0.01, up 25.00%, on 332,104 volume with 19 trades. The average volume for the last 60 days is 229,767 and the stock's 52-week low/high is $0.0023/$0.045.

graphic

The QualityStocks
Company Corner

graphic
graphic

Growblox Sciences, Inc. (GBLX)

The QualityStocks Daily Newsletter would like to spotlight Growblox Sciences, Inc. (GBLX). Today, Growblox Sciences, Inc. closed trading at $0.39, up 11.59%, on 97,743 volume with 44 trades. The stock’s average daily volume over the past 60 days is 61,729, and its 52-week low/high is $0.151/$1.51.

Growblox Sciences, Inc. announced today that the first of the planned four Cultivation Labs, a 30,000 square foot facility in Las Vegas, is scheduled to open in Las Vegas by the end of the fourth quarter. See below for recently taken pictures of both the exterior and interior of our Cultivation Lab as we share our updated progress with shareholders.

Growblox Sciences, Inc. (GBLX), a biopharmaceutical research and development company, is focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies for various medical conditions. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.

The company’s GrowBLOX technology suite includes the TissueBLOX, GrowBLOX, and CureBLOX equipment. Together, these components provide unparalleled control and monitoring of cannabis cultivation throughout the plant's life-cycle. These patent pending processes were designed to produce a safe and consistent cannabis product under cGMP guidelines. Utilizing a computer-regulated system that optimizes the nutrients, water, temperature, and gas levels, the GrowBLOX suite produces cannabis with more active ingredients per pound than traditional cultivation methods.

Also, based on an analysis of preclinical and clinical data from thousands of peer-reviewed studies, Growblox Sciences has identified the most effective profiles of cannabinoids and terpenes for the treatment of conditions within seven therapeutic categories. As a result of this extensive research and the analysis of the active ingredient profiles of 30,000 Cannabis strains in conjunction with a major testing lab, the company will be able to provide patients with natural cannabis strains containing the ideal ratios for treating specific diseases or symptoms.

Another significant advantage held by the company stems from an accelerated drug development program to finish in 3-5 years instead of the 15-20 years typically seen in traditional pharmaceutical development programs. Armed with an intellectual property strategy that takes full advantage of the design of the GrowBLOX technology suite and protects the valuable foundation laid, Growblox Sciences has positioned itself well for long-term success in the burgeoning cannabis space. Disclaimer

Growblox Sciences, Inc. Company Blog

Growblox Sciences, Inc. News:

GrowBLOX Sciences Announces First of Four Cultivation Labs Scheduled to Open in Las Vegas

GrowBLOX Sciences Secures Four New Nevada State Medical Cannabis Licenses

GrowBLOX Sciences Appoints Former Nevada State Senator Sandra Tiffany as New General Manager

On the Move Systems, Inc. (OMVS)

The QualityStocks Daily Newsletter would like to spotlight On the Move Systems, Inc. (OMVS). Today, On the Move Systems, Inc. closed trading at $0.8398, off by 7.82%, on 207,913 volume with 71 trades. The stock’s average daily volume over the past 60 days is 80,198, and its 52-week low/high is $0.2501/$11.04.

On the Move Systems, Inc. is on the lookout for possible partners in the freight brokerage industry and elsewhere that would add depth and value to the company’s launch of its upcoming “Uber-for-Trucking” online platform, now under development.

On the Move Systems, Inc. (OMVS) specializes in the development of cutting-edge technology to transform and synchronize freight supply chain operations for a broad range of industries. The company is exploring new online tools to reduce costs and increase convenience in the tourism and travel industry, as well as new opportunities in trucking. OMVS works with a premier group of international providers to offer its services in two key divisions: Trucking Logistics and Inter-modal Freight.

Logistics are critical to the success of any operation. OMVS's Trucking Logistics division operates as one of the most competitive, full-service transportation logistics providers in the United States. Utilizing the company's ISTx Platform, this division helps customers strategize how to get from one point to another, as well as solves some of the toughest logistics challenges on the road today. OMVS's Trucking Logistics technology provides customers increased visibility, minimal-cost route effectiveness, and delivery assurance.

OMVS's Intermodal Freight division offers seamless cargo continuation, tracking, shipping and receiving of goods anywhere in the world. The company's customer service teams and drivers communicate through the ISTx Platform allowing for flexibility, control and monitoring of each freight shipment. OMVS continues to research and explore the most effective and resourceful tools in order to effectively serve customers with unique shipping requirements in the billion dollar trucking industry.

In his more than 20 years of experience, OMVS president and CEO Robert Wilson has cultivated vast expertise as an executive and financial consultant for companies in aviation, energy, oil and gas, IT and healthcare. In addition to his work valuing and assessing small-to-middle market companies, Wilson has also served as both an officer and director of such client companies. Wilson applies his expertise in the transportation business and investment banking to spearhead OMVS's new initiative to create a new kind of online transportation platform to an international market Disclaimer

On the Move Systems, Inc. Company Blog

On the Move Systems, Inc. News:

OMVS Searching for Potential Joint Venture Partners as Shared Economy App Nears Launch

OMVS: Coming Capacity Shortage Opens Opportunity for Shared Economy Trucking App

OMVS: Shared Economy Courier Service Can Solve Multi-Channel Sourcing Needs

Cherubim Interests, Inc. (CHIT)

The QualityStocks Daily Newsletter would like to spotlight Cherubim Interests, Inc. (CHIT). Today, Cherubim Interests, Inc. closed trading at $0.0016, on 9,009,274 volume with 36 trades. The stock’s average daily volume over the past 60 days is 1,131,065, and its 52-week low/high is $0.0017/$0.5535.

Cherubim Interests, Inc. today announces the launch of its updated corporate website (www.CherubimInterests.com). In addition to enhanced visual appeal, key features include an Investors Center, along with thorough descriptions of the Company's products and operations, key leadership, market opportunities, and more.

Cherubim Interests, Inc. (CHIT) is a development-stage alternative construction and real estate development company seeking various opportunities relative to the company's management team of experts in property management, construction and finance.

The company's primary focus is within the real estate development and controlled environment agriculture sectors, which Cherubim recently entered into by acquiring an exclusive worldwide license for the deployment of a proprietary plant cultivation technology. Through its wholly owned subsidiary, BudCube Cultivation Systems USA, Cherubim plans to construct, deploy and lease scalable medical and recreational marijuana cultivation facilities for commercial applications.

Coupled with a real estate development and property management business model, BudCube Cultivation Systems ("BCS") can position itself anywhere in the world where the cultivation of cannabis is legal. BCS's unique business model positions the company to greatly benefit as more market participants seek to gain entry into a fast-growing market at an attractive price point.

Armed with the ability to lease a portable and scalable turn-key cultivation solution to growers, Cherubim aims to use its licensed solution to fill the gap for both first-time and experienced cultivators who may not have the capital resources to buy land, construct or tenant-improve existing structures for the optimum environment for developing a high-quality cannabis product. Disclaimer

Cherubim Interests, Inc. Company Blog

Cherubim Interests, Inc. News:

Cherubim Interests, Inc. Introduces New Corporate Website to Better Showcase Operations, Updates

Cherubim Interests, Inc. (CHIT) Announces Engagement of QualityStocks Investor Relations Services

Cherubim Interests Inc. Acquires License to Enter Controlled Environment Agriculture Industry

Avant Diagnostics, Inc. (AVDX)

The QualityStocks Daily Newsletter would like to spotlight Avant Diagnostics, Inc. (AVDX). Today, Avant Diagnostics, Inc. closed trading at $0.325, up 62.34%, on 12,315 volume with 14 trades. The stock’s average daily volume over the past 60 days is 2,336, and its 52-week low/high is $0.2002/$1.95.

Avant Diagnostics, Inc. (AVDX) is a medical diagnostic technology company that specializes in large panel biomarker screening. The company's first test, OvaDx®, is a sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.

In clinical development, OvaDx has indicated high sensitivity and specificity for all types and stages of ovarian cancer, including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous and ovarian adenocarcinoma. Upon FDA approval, Avant plans to offer its diagnostic product as an elective test for women seeking greater wellness, as well as those in the elevated risk category for ovarian cancer.

OvaDx is also expected to be used by doctors to advance the forefront of ovarian cancer treatment, promoting the utilization of improved surgical options and more effective chemotherapies by serving as a supplement to existing tests, such as CA-125, OVA1® and transvaginal ultrasound. In this way, Avant's innovative product will promote earlier diagnoses and, as a result, improved survival rates for patients with ovarian cancer.

As it continues to seek FDA approval for its groundbreaking diagnostic technology, Avant is poised to promote considerable growth in the ovarian cancer market, addressing what is currently the most deadly cancer of the female reproductive system. The company will lean on the industry experience of its management team in order to continue positioning itself for long-term success in the medical diagnostic market. Disclaimer

Avant Diagnostics, Inc. Company Blog

Avant Diagnostics, Inc. News:

Avant Diagnostics Inc. Engages Goal Capital Inc. to Provide Investor Relations Services

Avant Diagnostics, Inc. Appoints Marcum LLP as Its New Independent Registered Public Accounting Firm

Avant Diagnostics, Inc. Retains Sichenzia Ross Freidman Ference LLP as Its Corporate Counsel

Galenfeha, Inc. (GLFH)

The QualityStocks Daily Newsletter would like to spotlight Galenfeha, Inc. (GLFH). Today, Galenfeha, Inc. closed trading at $0.3044, up 21.76%, on 16,050 volume with 8 trades. The stock’s average daily volume over the past 60 days is 64,332, and its 52-week low/high is $0.1011/$4.00.

Galenfeha, Inc. (GLFH) is an engineering, product development, and manufacturing company that provides innovative solutions for oil and natural gas production, as well as stored energy products across a number of different industries. The company provides these products and services through its stored energy and oil & gas division.

Through its stored energy division, Galenfeha offers one of the most powerful, environmentally friendly battery systems in the market. The batteries have onboard computers, are inherently safe, internally temperature regulated, have optional GPS monitoring capabilities, offer significant weight reduction of up to 50%, and are engineered specifically for each type of application. Features include 100% “green” chemistry, RoHS compliancy, and active short circuit protection control.

Through its oil and gas division, the company offers chemical injection pumps that merge the perceived benefits of a hybrid, electric over pneumatic system. Galenfeha management believes the combination of the two parameter control systems represents a measurable shift in efficiency, reliability, cost management, and profitability to individual well locations as well as entire production fields. The combined technologies have demonstrated increased chemical injection accuracy, reducing chemical contamination in the production process while controlling cost and waste.

The company’s unwavering dedication is to continuously develop products that perform better than conventional solutions while also reducing environmental impact. Leveraging the management team’s wealth of resources and relationships, Galenfeha is well positioned for continued growth as the company aims to expand in both the stored energy and oil & gas industries. Disclaimer

Galenfeha, Inc. Company Blog

Galenfeha, Inc. News:

Galenfeha Introduces iWaV Control System Innovation

Galenfeha Announces Exclusive West Texas Distributor

Galenfeha, Inc. Products Offered by Leading Power and Automation Company

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

QualityStocks
(AVDX)

2.

Investor News Source
(ACOL)

3.

PennyStocks24
(APRE)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251